Klaria Inerim Report Q2 2026
Klaria Pharma reported Q2 net sales of 0.0 MSEK, flat year-over-year, while R&D expenses decreased to 4.4 MSEK from 7.1 MSEK. The company narrowed its net loss to -12.9 MSEK from -20.1 MSEK in the prior year, with EPS improving to -0.05 SEK.
Key figures
- Eps
- -0.05 SEK
- Revenue
- 0.0 MSEK
- Rd expenses
- 4.4 MSEK
- Group equity
- -33.6 MSEK
- Liquid assets
- 8.5 MSEK
- Profit after tax
- -12.9 MSEK
- Cash flow from operations
- -14.8 MSEK
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.